%0 Journal Article
%A Cortés-Ibáñez, Francisco O
%A Johnson, Theron
%A Mascalchi, Mario
%A Katzke, Verena
%A Delorme, Stefan
%A Kaaks, Rudolf
%T Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI).
%J Scientific reports
%V 14
%N 1
%@ 2045-2322
%C [London]
%I Macmillan Publishers Limited, part of Springer Nature
%M DKFZ-2024-00610
%P 7197
%D 2024
%Z #EA:C020#LA:C020#
%X Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany ('LUSI' study) serum cTnI was measured by high-sensitivity assay in blood samples collected at baseline, and categorized into unquantifiable/low (< 6 ng/L), intermediate (≥ 6-15 ng/L), and elevated (≥ 16 ng/L). Cox proportional-hazard models were used to estimate risk of all-cause and cardiac mortality with cTnI levels. After exclusion criteria, 3653 participants were included for our analyses, of which 82.4
%K Biomarkers (Other)
%K Lung cancer screening (Other)
%K Mortality (Other)
%K Myocardial infarction (Other)
%K Risk assessment (Other)
%K Troponin (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38531926
%R 10.1038/s41598-024-57889-z
%U https://inrepo02.dkfz.de/record/289143